Mirum Pharmaceuticals Liabilities 2025

Mirum Pharmaceuticals Aktienanalyse

What does Mirum Pharmaceuticals do?

Mirum Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and marketing of therapeutics for rare intestinal diseases. The company was founded in 2018 in California, USA and has experienced rapid growth since then. The company was founded after an unusual event in 2015 when Shire Pharmaceuticals plc, a large British pharmaceutical company, acquired the biotech company Lumena Pharmaceuticals Inc. The management of Lumena discovered a compound that they believed could relieve cholestasis, a condition where bile cannot flow adequately and therefore remains in the liver. They realized that this compound, if modified and used in a new formulation, could also be used to treat other rare intestinal diseases. The management of Lumena decided to pursue this idea and thus founded Mirum Pharmaceuticals Inc. The company's business model is to develop novel medications for the treatment of severe and rare intestinal diseases through a combination of in-house research and external collaborations. Mirum Pharmaceuticals Inc aims to fill a niche focusing on smaller patient populations that are often overlooked by larger pharmaceutical companies due to their rarity. The company also aims to work closely with patients and their families to ensure that their needs and concerns are incorporated into their product development processes. Currently, Mirum Pharmaceuticals Inc's research and development efforts focus on two main areas: cholestasis and intestinal enteropathies. Cholestasis is a condition where the liver is unable to secrete bile into the intestine, resulting in the accumulation of bile in the body and damage to liver cells and other organs. Mirum Pharmaceuticals Inc is currently developing Maralixibat, a medication targeting the treatment of intrahepatic cholestasis in children. Intestinal enteropathies are rare intestinal diseases characterized by a disruption of the intestinal tract. Mirum Pharmaceuticals Inc is dedicated to researching and developing a medication for the treatment of PFIC, a rare condition where bile fluid is no longer adequately excreted. In this regard, the company has entered into an agreement with Dova Pharmaceuticals Inc., which was acquired by Merck&Co. in mid-2019. Under this agreement, Mirum Pharmaceuticals Inc acquired the rights to a medication for the treatment of PFIC developed by Dova. Mirum Pharmaceuticals solutions aim to treat patients on a relevant basis and provide support for families and caregivers of patients. In summary, Mirum Pharmaceuticals Inc is a biopharmaceutical company that emerged from a spin-out of Lumena Pharmaceuticals Inc from Shire. It has focused on the development of therapeutics for rare intestinal diseases and works closely with patients and their families to ensure their concerns are considered in product development processes. The product research of Mirum Pharmaceuticals Inc currently focuses on Maralixibat, a medication for the treatment of intrahepatic cholestasis, as well as Mirum Pharmaceuticals Inc, a medication for the treatment of PFIC. Mirum Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Mirum Pharmaceuticals's Liabilities

Mirum Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Mirum Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Mirum Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Mirum Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Mirum Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Mirum Pharmaceuticals stock

What is the level of liabilities of Mirum Pharmaceuticals this year?

Mirum Pharmaceuticals has a debt balance of 397.95 M USD this year.

What were the liabilities of Mirum Pharmaceuticals compared to the previous year?

The liabilities of Mirum Pharmaceuticals have increased by 88.69% increased compared to the previous year.

What are the consequences of high debt for investors of Mirum Pharmaceuticals?

High liabilities can pose a risk for investors of Mirum Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Mirum Pharmaceuticals?

Low liabilities mean that Mirum Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Mirum Pharmaceuticals affect the company?

An increase in liabilities of Mirum Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Mirum Pharmaceuticals affect the company?

A decrease in the liabilities of Mirum Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Mirum Pharmaceuticals?

Some factors that can influence the liabilities of Mirum Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Mirum Pharmaceuticals so important for investors?

The liabilities of Mirum Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Mirum Pharmaceuticals take to modify the liabilities?

To change its liabilities, Mirum Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Mirum Pharmaceuticals pay?

Over the past 12 months, Mirum Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirum Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirum Pharmaceuticals?

The current dividend yield of Mirum Pharmaceuticals is .

When does Mirum Pharmaceuticals pay dividends?

Mirum Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirum Pharmaceuticals?

Mirum Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Mirum Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirum Pharmaceuticals located?

Mirum Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirum Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirum Pharmaceuticals from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.

When did Mirum Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/15/2025.

What was the dividend of Mirum Pharmaceuticals in the year 2024?

In the year 2024, Mirum Pharmaceuticals distributed 0 USD as dividends.

In which currency does Mirum Pharmaceuticals pay out the dividend?

The dividends of Mirum Pharmaceuticals are distributed in USD.